In the latest trading session, 0.44 million Candel Therapeutics Inc (NASDAQ:CADL) shares changed hands as the company’s beta touched -1.32. With the company’s most recent per share price at $11.02 changed hands at -$0.61 or -5.23% at last look, the market valuation stands at $490.18M. CADL’s current price is a discount, trading about -32.49% off its 52-week high of $14.60. The share price had its 52-week low at $1.34, which suggests the last value was 87.84% up since then.
Analysts gave the Candel Therapeutics Inc (CADL) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 1 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended CADL as a Hold, 1 felt it is a Buy and 0 rated the stock as Underweight. Candel Therapeutics Inc’s EPS for the current quarter is expected to be -0.23.
Candel Therapeutics Inc (NASDAQ:CADL) trade information
Instantly CADL was in red as seen in intraday trades today. With action 21.78%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 26.97%, with the 5-day performance at 21.78% in the green. However, in the 30-day time frame, Candel Therapeutics Inc (NASDAQ:CADL) is 56.11% up.
Candel Therapeutics Inc (CADL) estimates and forecasts
According to analysts, the company will likely register a growth in its current quarter sales, forecast at 0.00%. Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -46.75%. The 2025 estimates are for Candel Therapeutics Inc earnings to decrease by -4.53%, but the outlook for the next 5-year period is at 0.88% per year.
Candel Therapeutics Inc (NASDAQ:CADL)’s Major holders
BLACKROCK INC. holds the second largest percentage of outstanding shares, with 2.819% or 0.82 million shares worth $5.1 million as of 2024-06-30.
Among Mutual Funds, the top two as of Dec 31, 2024 were Fidelity Select Portfolios – Biotechnology and iShares Russell 2000 ETF. With 3.92 shares estimated at $42.37 million under it, the former controlled 12.06% of total outstanding shares. On the other hand, iShares Russell 2000 ETF held about 1.71% of the shares, roughly 555.0 shares worth around $6.01 million.
